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Abstract
Background: All patients with liver cirrhosis are recommended to undergo an evaluation of
esophageal varices (EV) to assess their risk of bleeding. Predicting the presence of EV through non-
invasive means may reduce a large number of unnecessary endoscopies. This study was designed
to develop a predictive model for varices in patients with Hepatitis B virus-related cirrhosis.
Methods: The retrospective analysis was performed in 146 patients with Hepatitis B virus-related
cirrhosis. The data were assessed by univariate analysis and a multivariate logistic regression
analysis. In addition, the receiver operating characteristic curves were also applied to calculate and
compare the accuracy of the model and other single parameters for the diagnosis of esophageal
varices.
Results: We found the prevalence of EV in patients with Hepatitis B virus-related cirrhosis to be
74.7%. In addition, platelet count, spleen width, portal vein diameter and platelet count/spleen
width ratio were significantly associated with the presence of esophageal varices on univariate
analysis. A multivariate analysis revealed that only the spleen width and portal vein diameter were
independent risk factors. The area under the receiver operating characteristic curve of regression
function (RF) model, which was composed of the spleen width and portal vein diameter, was higher
than that of the platelet count. With a cut-off value of 0.3631, the RF model had an excellent
sensitivity of 87.2% and an acceptable specificity of 59.5% with an overall accuracy of 80.1%.
Conclusion: Our data suggest that portal vein diameter and spleen width rather than platelet
count may predict the presence of varices in patients with Hepatitis B virus-related cirrhosis, and
that the RF model may help physicians to identify patients who would most likely benefit from
screenings for EV.
Background
Most cirrhotic patients develop esophageal varices, with a
lifetime incidence as high as 90% [1]. Approximately one
third of cirrhotic patients with esophageal varices (EV)
develop an episode of esophageal hemorrhage, and sub-
sequently have high morbidity and mortality [1]. There-
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patients are crucial to minimizing complications. An
endoscopy examination is currently considered to be the
gold standard. However, screening all patients with
endoscopy to guide therapy may significantly increase the
cost.
Non-invasive indicators of varices are desired to reduce
the need for screening endoscopy in all patients with cir-
rhosis. Studies shows that platelet count, splenomegaly,
platelet count/spleen diameter ratio, advanced Child-
Pugh class, serum albumin, and high portal vein diameter
measured by ultrasonography may be useful non-invasive
predictors of EV for patients with cirrhosis [2-4]. Such pre-
dictive factors may be expected to vary in different popu-
lations because of differences in the etiologies of liver
cirrhosis and severity of liver disease. Data on this aspect
in Chinese patients with liver cirrhosis, who usually have
a higher proportion with hepatitis B viral etiology, remain
largely unexplored. Here in this retrospective study, we
evaluated the utility of various clinical, biochemical and
ultrasonographic parameters in developing a model for
predicting the presence of EV in Chinese patients with
HBV-related cirrhosis.
Methods
This study included a total of 146 patients with HBV
(Hepatitis B virus)-related cirrhosis that attended at our
hospital between July 2005 and July 2007. Exclusion cri-
teria included: active bleeding; current alcohol intake
(patients with alcohol-related liver cirrhosis were
excluded even if abstinent for at least 6 months prior to
endoscopy); previous endoscopic sclerosis or band liga-
tion of EV; previous surgery for portal hypertension or
transjugular intrahepatic porto-systemic stent shunt
placement. None of the patients were treated with β-
blocker or diuretics. Hepatocellular carcinoma, spontane-
ous bacterial peritonitis, or portal vein thrombosis were
also excluded for the study.
The following information was collected for each patient:
age, gender, biochemical parameters including aspartate
aminotransferase (AST), alanine aminotransferase (ALT),
ALT/AST ratio, total bilirubin, conjugated bilirubin, total
protein, serum albumin, prothrombin time, prothrombin
activity (%), alkaline phosphatase, γ-glutamyl transpepti-
dase (GT), platelet count, presence and degree of ascites
and encephalopathy assessed according to Child-Pugh cri-
teria [5]. Diuretics therapy was not commenced before
endoscopy and ultrasonography was performed. The pres-
ence and size of EV were determined and recorded for
each patient. The size of varices was subdivided into two
classes–small and large according to the criteria proposed
at the Baveno I Consensus Conference [6]. Small EV were
defined as varices that flatten with insufflation or mini-
mally protrude into the esophageal lumen, while large EV
were defined as varices that protrude into the esophageal
lumen and touch each other (presence of confluence), or
that fill at least 50% of the esophageal lumen. This study
protocol was approved by the Ethic Committee of the First
Affiliated Hospital of Wenzhou Medical College.
All patients underwent ultrasonographic examination of
the upper abdomen including measurement of spleen
width and portal vein diameter. The platelet count/spleen
width ratio in all patients was then calculated. Ultrasono-
graphic measurement of spleen width on a longitudinal
section with the patient in the right lateral decubitus posi-
tion was technically feasible in all patients as described by
Lamb et al [7]. The intra- and inter-observer coefficients of
variation for measuring the spleen width were evaluated
in 50 patients and were 1.2% and 2.1%, respectively.
All data were analyzed by STATA 10.0 software. Continu-
ous values were expressed by mean ± SD or median and
interquartile range and compared using the Student's t-
test or the Mann-Whitney non-parametric test. Categori-
cal values were described by count and proportions and
compared by the χ2 test. Univariate analyses for determin-
ing the association of various clinical, laboratories and
ultrasonographic variables with the presence or absence
of EV were performed, and P-values below 0.05 were con-
sidered significant. All variables that were found to be dif-
ferent between patients with and without EV on
univariate analysis were included as candidate variables in
a forward-conditional step-wise logistic regression analy-
sis to identify independent predictors for the presence of
such varices. For this analysis, the conditional probabili-
ties for stepwise entry and removal of a factor were 0.05
and 0.10, respectively. Based on the results of multiple
logistic regression analysis, a logistic regression equation
was developed to predict EV. The receiver operating char-
acteristic curves (ROC curves) were applied to calculate
and compare various predictors for the diagnosis of EV.
The validity of the model was measured by means of the
area under receiver operating characteristic curve
(AUROC). A model with an AUROC above 0.7 was con-
sidered useful, while an AUROC between 0.8 and 0.9
indicated excellent diagnostic accuracy [4]. The optimum
cut-off value was chosen as the value corresponding with
the highest accuracy (minimal false sensitivity and false
positive results) for single variables, and various cut-off
values were investigated for the model to determine the
optimal cut-off values for predicting or excluding EV. The
sensitivity (Se), specificity (Sp), negative predictive value
(NPV), positive predictive value (PPV), and positive like-
lihood ratio (+LR), negative likelihood ratio (-LR) and
diagnostic accuracy (DA) were calculated for various cor-
responding cut-off values.Page 2 of 7
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Patient characteristics
Of the 146 patients included in the study, 99 (67.8%)
were male, with a mean age of 53.1 ± 12.2 years. Only
seven patients received antiviral treatment. The demo-
graphic and clinical characteristics of the patients are
shown in Table 1. EV were found in 109 patients (74.7%)
and large varices in 41 patients (28.1%). Prevalence of all
varices was 67%, 78%, and 75% in patients with Child-
Pugh class A, B and C cirrhosis respectively. As Child-Pugh
class was categorized into binary variable: Child-Pugh
class A versus advanced Child-Pugh class (Child-Pugh
class B or C), the prevalence of all varices in patients with
Child-Pugh class A was lower than that in patients with
advanced Child-Pugh class (67% versus 77%), which,
however, did not reach statistical significance (P = 0.25).
Ascites was found in 60.3% of patients by ultrasonogra-
phy and clinical examination. The mean portal vein diam-
eter of all patients was 12.6 ± 1.9 mm (range from 9 to 26
mm).
Variables associated with the presence of EV by univariate 
analysis
Twenty variables considered relevant to the presence of EV
were tested using univariate analysis. As shown in Table 2,
platelet count, spleen width, platelet count/spleen width
ratio, and portal vein diameter were significantly associ-
ated with the presence of EV.
Factors independently associated with EV
A multivariate analysis was performed by a logistic regres-
sion for all variables. As shown in Table 3, significant
independent association with the presence of EV was
found for the spleen width (p = 0.022) and portal vein
diameter (p = 0.009). In addition, a regression equation
was derived for predicting the presence of esophageal
varices. Regression function (RF) = -8.107529 +0.4758
(portal vein diameter) + 0.0708 (spleen width). The P-
value of this regression function is < 0.0001. We denomi-
nated it as the RF model. The Hosmer-Lomeshow good-
ness of fit test was significant (p = 0.4282), suggesting that
our prediction model fit the actual data well.
Diagnostic values of RF model, portal vein diameter, 
spleen width, platelet count and platelet count/spleen 
width ratio
The receiver operating characteristic (ROC) curve for RF
model, portal vein diameter, spleen width, platelet count
and platelet count/spleen width ratio for the prediction of
EV are shown in Figure 1. The RF model yielded the high-
est AUROC (0.777 ± 0.048) and the AUROC of it was sta-
tistically higher than that of the platelet count (AUROC =
0.660 ± 0.052, P = 0.0252) by a significant amount. How-
ever, the AUROC of the RF model was not substantially
different from the AUROC of portal vein diameter
(AUROC = 0.739 ± 0.047, P = 0.08), spleen width
(AUROC = 0.736 ± 0.049, p = 0.12), or platelet count/
spleen width ratio (AUROC = 0.7095 ± 0.0488, p = 0.10).
The AUROCs of the RF model, portal vein diameter,
spleen width, platelet count/spleen width ratio and plate-
let count were all > 0.5 statistically.
Based on the ROC curve analysis, the optimum cut-off val-
ues of portal vein diameter, spleen width, and platelet
count/spleen width ratio were 12 mm, 46 mm, 1.0153
(109/L)/mm, respectively (Table 4). The diagnostic per-
formances for different cut-off values of the RF model are
shown in Table 5.
Discussion
Thrombocytopenia in patients with cirrhosis has histori-
cally been attributed to hypersplenism due to portal
hypertension. Several studies suggest that platelet count
may predict the presence of EV in patients with cirrhosis
[2,8,9]. However, the discriminating threshold for the
presence of varices varies widely, ranging between 68,000
and 160,000/mm3 [10]. The sensitivities for thrombocy-
topenia fluctuate from 62% to 100%, and the specificities
range from 18% to 77% [11]. Our data suggest that the
multivariate analysis failed to show any significant differ-
ence between thrombocytopenia and the risk of EV. In
addition, platelet count might not be an ideal predictor of
the presence of EV in HBV-related cirrhosis. A possible
explanation is that other factors, such as suppressive
effects of viruses on bone marrow and antibody-mediated
destruction of platelets, may play a more important role
in HBV-related cirrhosis than that in alcohol cirrhosis, in
Table 1: Demographic and Clinical Characteristics of 146 
patients
Characteristic Data
Age (yr) 53.1 ± 12.2
Male (%) 67.8
Child-Pugh score 8(6–9)
Child-Pugh A/B/C (%) 25.4/50.0/24.6
Total Bilirubin (μmol/L) 45.5 ± 55.7
AST (IU/L) 80.5 ± 70.8
ALT (IU/L) 61.8 ± 66.9
Albumin (g/L) 31.8 ± 6.3
Prothrombin time (s) 18.4 ± 4.5
Platelets (109/L) 61.5 ± 37.9
Portal vein diameter (mm) 12.6 ± 1.9
Spleen width (mm) 50.6 ± 10.1
Data are shown either as number of observations, percentage or 
median ± SD except for Child-Pugh score (expressed as median and 
interquartile range)Page 3 of 7
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[12].
The prevalence of EV in this study is similar to previous
findings [13]. In addition, the prevalence of all varices in
patients with advanced Child-Pugh class was higher than
that in patients with Child-Pugh class A, which is also con-
sistent with previous observations that patients with
advanced liver disease are more likely to have varices [8].
However, this difference did not reach statistical signifi-
cance, which could be due to the small sample size of our
study. Data on the relationship between Child-Pugh score
and the risk of EV is somewhat conflicting. One study
showed that Child-Pugh score was an acceptable predictor
of the presence of EV [14], whereas a recent well-designed
study suggested that it was not a useful predictor [15]. Our
data do not support any correlation between Child-Pugh
score with varices, which may partially be due to a rather
homogeneous population in the present study, in which
50% of patients were Child-Pugh class B. As suggested by
Rajvanshi et al, the prevalence of EV increased with a
higher Child-Pugh class, but Child-Pugh score was not a
predictor of EV [16].
EV is the direct consequence of spontaneous formation of
collateral vessels between portal vein and esophageal
Table 2: Univariate analysis of predictive factors of EV in 146 patients
Variable Absence of varices N = 37 Presence of varices N = 109 P
Age (yr) 54.8 ± 13.6 52.5 ± 11.7 0.327
Male (%) 75.7 65.1 0.236
Child-Pugh score 8(6–9) 8(7–9) 0.789
Child-Pugh class 0.487
A 12(33%) 25(23%)
B 16(43%) 57(52%)
C 9(24%) 27(25%)
Total Bilirubin (μmol/L) 41.4 ± 40.7 46.9 ± 60.0 0.607
Conjugated bilirubin(μmol/L) 18.2 ± 21.0 20.6 ± 34.9 0.988
Total protein (g/L) 64.1 ± 5.3 63.2 ± 7.2 0.467
Albumin (g/L) 31.3 ± 6.2 31.9 ± 6.3 0.596
ALT (U/L) 75.6 ± 95.8 57.0 ± 51.8 0.139
AST (U/L) 91.5 ± 99.1 76.7 ± 58.3 0.273
ALT/AST ratio 0.79 ± 0. 33 0. 77 ± 0. 27 0.719
Alkaline phosphatase (U/L) 109.4 ± 41.0 108.9 ± 70.9 0.969
γ- GT (U/L) 115.6 ± 139.1 82.3 ± 94.6 0.106
Prothrombin time(s) 18.7 ± 5.5 18.3 ± 4.1 0.691
Prothrombin activity (%) 60.4 ± 17.9 60.7 ± 15.2 0.925
Platelets (109/L) 79.6 ± 51.1 55.3 ± 30.1 < 0.001
Ascites (%) 48.6 64.2 0.094
Platelets/Spleen width 1.89 ± 1.39 1.15 ± 0.82 < 0.001
Spleen width (mm) 44.8 ± 7.6 52.5 ± 10.1 < 0.001
Portal vein diameter (mm) 11.6 ± 1.3 12.9 ± 1.9 < 0.001
Data are shown either as percentage or median ± SD except for Child-Pugh score (expressed as median and interquartile range).
Table 3: Logistic regression model to predict the presence of EV in 146 patients
Variable Coefficient Odds Ratio (95% Confidence interval) P
Constant -8.107529
Spleen width (mm) 0.0708089 1.07 (1.01–1.14) 0.022
Portal vein diameter (mm) 0.4757532 1.61 (1.13–2.29) 0.009Page 4 of 7
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presence or absence of EV may reflect the severity of portal
hypertension. In a logistic regression study of 143 patients
[17], ultrasonographic portal vein diameter greater than
13 mm was one of the independent risk factors for the
presence of EV. However, another study [3] failed to con-
firm the predicting role of portal vein diameter when
using a cut-off value of 13 mm in prevalently HCV-related
cirrhosis. The results of the present study indicate that the
portal vein diameter with an AUROC of 0.739 could be a
valuable predictor of EV in patients with HBV-related cir-
rhosis. The fact that different studies conclude different
best cut-off values of the portal vein diameter may be
explained at least in part by that the physique of Asian
populations is smaller than that of European populations.
It has been reported that the normal mean portal vein
Receiver operating characteristic curves for various predictors of EVFigure 1
Receiver operating characteristic curves for various predictors of EV. The areas under receiver operating character-
istic curves were 0.777 ± 0.048, 0.739 ± 0.047, 0.736 ± 0.049, 0.7095 ± 0.0488, 0.660 ± 0.052 for the RF model, portal vein 
diameter (PVD), spleen width (SW), platelet count/spleen width ratio (PC/SWR) and platelet count (PC) respectively. The ideal 
area under the curve was 1.00. The reference line represents that based on chance alone (area under the curve 0.50).
Table 4: Performance of the portal vein diameter, spleen width and the platelet count/spleen width ratio for predicting the presence of 
EV.
Variable Best Cut-off Se (%) Sp (%) +LR -LR PPV (%) NPV (%) DA (%)
Portal vein diameter (mm) 12 83.5 56.8 1.93 0.29 85.1 53.8 76.7
Spleen width (mm) 46 71.6 75.7 2.94 0.38 89.7 47.5 72.6
Platelet count/Spleen width 1.0513 57.8 67.6 1.78 0.62 84.0 35.2 60.3
Se, sensitivity; Sp, specificity; +LR, positive likelihood ratio; -LR, negative likelihood ratio; PPV, positive predictive value; NPV, negative predictive 
value; DA, diagnostic accuracy; Prevalence of esophageal varices, 74.7% (109/146)Page 5 of 7
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while it is 11.0 ± 0.3 mm in French populations [19].
Splenomegaly is recognized as one of the diagnostic signs
of cirrhosis and portal hypertension. Several studies show
that splenomegaly may be a good predictor of EV
[2,9,20,21]. Lamb et al found that there was a good corre-
lation between in vivo ultrasound assessment of splenic
width and true splenic volume [7]. Our data showed that
spleen width measured by ultrasonography was an inde-
pendent predictor for the presence of varices with an
AUROC of 0.736. Contrary to what was suggested in pre-
vious reports, no correlation between splenomegaly and
EV was found in other studies [17,22,23]. These differ-
ences may be due to the variations among studies regard-
ing the etiology and the stage of liver cirrhosis studied.
Moreover, splenomegaly is found more frequently in
posthepatitic cirrhosis than in alcoholic cirrhosis [24].
With the best cut-off value of 1.0513 (109/L)/mm, the
platelet count/spleen width ratio yielded a low diagnostic
accuracy of 60.3%, which suggests that it is not an ideal
predictor for EV.
With a cut-off value of 0.3631, the RF model had an excel-
lent sensitivity of 87.2% and an acceptable specificity of
59.5% with an overall accuracy of 80.1%, which was
higher than that of spleen width and portal vein diameter.
And with a cut-off value of 0.1705, 82.2% of the patients
were correctly classified. However, our data showed that
the RF model had a moderate predictive power with an
AUROC of 0.777. Moreover, the other parameters listed in
Table 5 are also modest: the positive likelihood ratios of
the different cut-off values are rather low, and the negative
likelihood ratios are too high except for the cut-off -
0.3052. However, the specificity for the cut-off -0.3052 is
fairly low, which means that some of these patients with
splenomegaly and dilated portal vein may not have EV.
One of the possible explanations for this result could be
the development of spontaneous intra-abdominal shunts
that decrease the blood flow of varices while maintaining
congestive splenomegaly and dilated portal vein.
Our study has several limitations. First, the data were col-
lected retrospectively, so patients at a relatively more
advanced stage of the disease were more prone to be
enrolled in our study, while outpatients were more likely
to be excluded for insufficient data, which may produce a
population bias. Second, prediction models may vary
with the nature of the patient population from which
these are derived. The population of our study is largely
composed of patients with decompensated cirrhosis, and
only partially reflects the population in which an index to
predict the presence of varices would be mostly applied in
clinical practice, i.e. patients enrolled at the time of the
diagnosis of cirrhosis. This might have artificially
increased the performance of the prognostic index. The
predictability of variables in the RF model might not
apply to a patient or cohort with less advanced cirrhosis.
Prospective validation in an independent patient popula-
tion is mandatory. Whereas the authors have to state
clearly that until this is done, the model should not be
used as a substitute for endoscopy because the parameters
of the model are all modest. Third, the performance char-
acteristics of the index is globally modest – the AUROC is
inferior to that of other indexes such as the platelet count/
spleen diameter ratio [4,25,26], CT esophagography [27],
all of which are recently considered as excellent predictors
for EV. It will be interesting and necessary to analyze these
predictors in comparison in future studies.
Although the present study has the above-mentioned lim-
itations, it is the first study, to the best of our knowledge,
to investigate predictors of EV in HBV-related cirrhosis in
homogeneous population. In addition, the platelet
count/spleen width ratio and the spleen width on ultra-
sonography were first introduced as potential predictors
of EV. The intra- and inter-observed variability for the
spleen width measurement is good, so it is reproducible.
The RF model with a certain cut-off value has a much
higher sensitivity and NPV for ruling out the presence of
EV and higher diagnostic accuracy than that of single pre-
dictors such as the platelet count/spleen width ratio, the
spleen width, the portal vein diameter.
Conclusion
Portal vein diameter and spleen width but not platelet
count may predict the presence of varices in hepatitis B
virus-related cirrhosis. The RF model may also help clini-
cians to identify patients who would most likely benefit
from referrals for screening for esophageal varices. How-
ever, these findings, including the validity of the model,
need to be verified with prospectively collected data.
Endoscopic screening for EV may be recommended in
Table 5: Diagnostic values of RF model for predicting EV at 
various cut-off points.
Cut-off Se (%) Sp (%) +LR -LR PPV (%) NPV (%) DA (%)
-03052 99.1 16.2 1.18 0.06 77.1 85.7 77.4
0.0997 95.4 40.5 1.60 0.11 82.6 74.8 81.5
0.1705 93.6 48.7 1.82 0.13 84.3 72.0 82.2
0.2214 90.8 48.6 1.79 0.17 83.9 64.1 80.8
0.3631 87.2 59.5 2.15 0.22 86.4 61.2 80.1
0.5445 82.6 62.2 2.18 0.28 86.6 54.8 77.4
0.7879 74.3 73.0 2.75 0.35 89.0 49.0 73.3
1.6177 50.0 83.8 3.11 0.59 90.2 36.5 60.3
3.014 13.8 100 0 0.86 100 38.2 35.6
Se, sensitivity; Sp, specificity; +LR, positive likelihood ratio; -LR, 
negative likelihood ratio; PPV, positive predictive value; NPV, negative 
predictive value; DA, diagnostic accuracy; Prevalence of esophageal 
varices, 74.7% (109/146);Page 6 of 7
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dilated portal vein.
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